"We continue to evaluate opportunities and going forward acquisitions in the US would have to satisfy our multiple aspirations of creating a meaningful speciality business, bolstering our existing brands business and acquiring technological capabilities that we would like to work on," Lupin Ltd CFO S Ramesh told PTI.
The company continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and skin diseases segments, he added.
Terming the US as a high growth market for the company, the Mumbai-based firm said it aims to grow at around 25 per cent in the world's largest drug market.
"For Lupin, the US is a high growth market and the major contributor to the company's overall revenues and profitability... We don't give guidances but if the past is prescriptive of the future we would aim to maintain our current growth momentum for the US market between 20-25 per cent," Ramesh said.
The company remains the 5th largest and fastest growing top five generic players in the US for the third year now, he added.
As per IMS Health data, Lupin currently has close to 5.4 per cent market share of the overall US generics market.
The US formulation sales contributed 44 per cent to the company's overall consolidated revenue for FY14.
US revenues grew by 16 per cent to USD 803 million during FY14 out of which the generic business contributed USD 723 million.
As of June 30, 2014, the company's cumulative abbreviated new drug application (ANDA) filing with the US Food and Drug Administration (USFDA) stood at 200 with the company having received 103 approvals.
"Currently 97 ANDA's are pending for approval and launch; addressing an opportunity of over USD 80 billion... 31 filings out of which are first-to-file (FTF) opportunities," Ramesh said.
Shares of Lupin were trading 1.52 per cent down at Rs 1,364 apiece on the BSE.